Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
SU9516
Cat. No.:
OB0225LY-0279
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
SU9516 is a small molecule compound used as a CDK inhibitor for cell cycle studies.
Synonym:
377090-84-1; SU 9516; 1,3-Dihydro-3-(1H-imidazol-5-ylmethylene)-5-methoxy-2H-indol-2-one; 3-((1H-Imidazol-5-yl)methylene)-5-methoxyindolin-2-one; (Z)-3-((1H-Imidazol-4-yl)methylene)-5-methoxyindolin-2-one; (3Z)-1,3-Dihydro-3-(1H-imidazol-5-ylmethylene)-5-methoxy-2H-indol-2-one;
CAS No.:
377090-84-1
Compound CID:
5289419
Formula:
C13H11N3O2
Formula Weight:
241.25
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
SU9516 can be used in cell proliferation studies or play an important role in tumor cell cycle regulation.
Library Information
Targets:
CDK family; PKC family; MAPK family
Receptors:
CDK1; CDK2; CDK4; p38; PKC
Pathways:
Cytoskeletal signaling; Apoptosis; Cell cycle/Checkpoint; Autophagy; MAPK; Chromatin/Epigenetic
Plate Number:
AOCL-4
Plate Location:
e8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
55 mg/mL; 227.98 mM
Ethanol Max Solubility:
4.8 mg/mL; 20 mM
